Therachon, a Basel, Switzerland-clinical-stage biotechnology company focused on rare diseases, completed a $60m mezzanine financing.
The round was led by Novo Holdings with participation from new investors Cowen Healthcare Investments, Pfizer Ventures and funds managed by Tekla Capital Management, we well as existing investors Versant Ventures, OrbiMed, Bpifrance and Inserm Transfert Initiative. In conjunction with this financing, Jørgen Søberg Petersen M.D., Ph.D., DMSc, MBA, venture partner at Novo Holdings, and Timothy Anderson, director, Cowen Healthcare Investments, have been appointed members of Therachon’s Board of Directors.
The company plans to use the proceeds to advance its lead pipeline candidate TA-46, a novel protein therapeutic for achondroplasia.
Led by Luca Santarelli, M.D., chief executive officer, and Thomas F. Woiwode, Ph.D., Chairman of the Board and managing director at Versant Ventures, Therachon is a clinical-stage global biotechnology company focused on developing medicines for rare diseases with significant unmet need. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of disproportionate short stature in humans.